Advanced lipid testing is changing how we assess cardiovascular risk. Instead of making decisions from a single number on a standard cholesterol panel, functional medicine uses particle counts, inflammatory markers, genetics, and hormone status to build a far more accurate picture of what is actually happening inside your arteries.
At The Fork Functional Medicine, we do not treat LDL as the whole conversation. We treat it as one data point among many. Heart disease remains the leading cause of death in this country, and the tools to assess it properly have existed for years. Most people simply are not being offered them.
Today we will cover what you need to know about advanced cholesterol testing and how we use it in clinical practice. Keep reading as we explore:
For decades, the message has been simple: LDL is the "bad" cholesterol, lower is better, and a statin is the answer. The research is considerably more complicated than that.
A large retrospective cohort study published in BMJ Open followed 177,860 adults aged 50 to 89 who had no diabetes, no history of heart disease, and were not taking statins. Researchers found a U-shaped relationship between LDL cholesterol and long-term mortality, with the lowest risk falling across a wide range of 100 to 189 mg/dL. That is considerably higher than the target most patients are given.
The study was carefully designed to address the obvious objection. Patients who died within the first year were excluded, as were those with extremely low baseline cholesterol, because serious illness lowers cholesterol and can make low numbers look dangerous when they are simply a marker of being sick.
Here is what we find most interesting. Two other measures in that same dataset did predict mortality clearly: the total cholesterol to HDL ratio, and the triglyceride to HDL ratio. The triglyceride to HDL ratio showed a clean gradient, with the lowest group carrying roughly 24 percent lower adjusted mortality risk than the highest.
So lipids absolutely predict risk. We may simply be reading the wrong line on the report.
A second study, published in the Journal of Cardiovascular Development and Disease, looked at the other end of the spectrum. Among 1,579 statin-naive patients admitted with acute coronary syndrome, 15 percent arrived with normal LDL cholesterol at the time of their cardiac event. Their coronary disease burden, measured by Syntax score, was identical to the high-LDL group. Their mortality was significantly higher.
The authors concluded that something is missing from the picture beyond coronary anatomy, procedural optimization, and LDL numbers. They named inflammation and lipoprotein(a) as the leading candidates.
That is precisely the gap advanced testing is designed to close.
Standard LDL-C measures how much cholesterol is carried inside your LDL particles. It tells you nothing about how many particles are carrying it.
Picture two people with an identical LDL-C of 110 mg/dL. One is carrying that cholesterol in a modest number of large, buoyant, well-loaded particles. The other is carrying the same amount in a much larger fleet of small, dense, cholesterol-poor particles.
Same number. Very different risk.
Atherosclerosis is not driven by how much cholesterol is floating in your blood. It is driven by how many particles are colliding with your artery wall and lodging there. More particles, more opportunities for injury.
This mismatch is called discordance, and it is not a rare exception. It appears constantly in people with insulin resistance, elevated triglycerides, and low HDL. Which is exactly the pattern that predicted mortality in the research above.
Personalized cardiovascular risk assessment requires personalized data. Here is what a comprehensive panel includes and why each marker matters.
Your cholesterol panel is not a fixed trait. It shifts with your hormones, and the relationship runs in both directions, because cholesterol is the raw material your body uses to build steroid hormones in the first place.
Pregnenolone, progesterone, testosterone, and estradiol all begin as cholesterol and are modified down a shared biochemical pathway. The molecule most people treat as a pure liability is also the feedstock for your sex hormones, your cortisol, and your vitamin D.
Estrogen signals the liver to produce more LDL receptors. More receptors means faster clearance of LDL particles from circulation. When estradiol declines, that clearance slows and particles remain in circulation longer.
The Study of Women’s Health Across the Nation quantified this. Total cholesterol, LDL-C, and apoB all increased sharply within the one-year window surrounding the final menstrual period, not gradually across midlife. The effect held after adjusting for age, weight, weight gain, and medication use, and it was consistent across every ethnic group studied.
In other words, this was ovarian aging, not chronological aging. A woman whose LDL climbs twenty points at 51 has not necessarily changed a thing about her diet.
The HDL findings from that same cohort make our earlier point beautifully. Across the menopause transition, HDL-C actually rose. But when researchers examined the subclasses, large HDL particles declined, small particles increased, and cholesterol efflux capacity per particle fell. The number improved while the function deteriorated. Reading HDL-C alone would have given you exactly the wrong impression.
Low testosterone in men travels with a recognizable pattern: elevated triglycerides, reduced HDL, increased visceral fat, and greater insulin resistance. This is the same atherogenic dyslipidemia that produces small, dense particles.
The direction of causation is genuinely tangled. Visceral fat lowers testosterone, and low testosterone makes visceral fat easier to accumulate. The lipid changes may be traveling with the body composition rather than being driven by the hormone alone.
Replacement therapy data reflect that complexity. Some studies in hypogonadal men show reductions in total cholesterol and LDL. Others show HDL declining, particularly the large HDL2 subfraction and particularly at higher doses. The honest summary is that effects are modest and formulation-dependent. Testosterone is not a lipid medication. We treat documented, symptomatic deficiency, and we monitor lipids as part of that care.
Progesterone on its own is relatively lipid-neutral. Where it matters enormously is in what is paired with estrogen, and the difference between bioidentical progesterone and synthetic progestins is substantial.
The Postmenopausal Estrogen/Progestin Interventions trial demonstrated this directly. Women receiving estrogen with micronized progesterone retained significantly more of estrogen’s HDL benefit than women receiving estrogen with medroxyprogesterone acetate. The likely explanation is that medroxyprogesterone carries androgenic and glucocorticoid activity that micronized progesterone does not, and that activity suppresses apolipoprotein A-I production in the liver.
Route of delivery matters as well. Oral estrogen passes through the liver first, lowering LDL more substantially but raising triglycerides. Transdermal estradiol bypasses that first pass and tends to be more triglyceride-neutral.
An important clarification: hormone therapy is not a cardiovascular prevention strategy, and no major guideline recommends it for that purpose. We treat symptoms and documented deficiency. We monitor the lipid effects. We do not prescribe hormones to move a cholesterol number.
If there is one thing in this article we wish every patient knew, it is this one.
Thyroid hormone is one of the most powerful regulators of cholesterol metabolism in the body, and an underactive thyroid is a well-established, entirely reversible cause of an elevated lipid panel. It is common. It is inexpensive to test for. And it is missed constantly.
The central mechanism is the same one estrogen uses. Active thyroid hormone, T3, stimulates transcription of the LDL receptor gene in the liver. Fewer LDL receptors means less LDL removed from circulation. Hypothyroidism reduces hepatic LDL receptor activity and slows LDL clearance, which is why cholesterol accumulates.
But the mechanism runs deeper than a single receptor. Thyroid hormone also influences HMG-CoA reductase, the same enzyme statins target. It affects cholesteryl ester transfer protein, hepatic lipase, and lipoprotein lipase activity, which is why triglyceride clearance slows as well. It regulates LDL receptor-related protein 1, which clears remnant particles after meals. And research has now shown that PCSK9, the protein that degrades LDL receptors, is part of the picture too.
There is also a genuinely surprising finding worth knowing. TSH appears to influence lipid metabolism independently of thyroid hormone itself, acting through receptors on liver and fat tissue. This is part of why the number matters even when free T4 still looks acceptable.
Overt hypothyroidism raises total cholesterol, LDL-C, apoB, lipoprotein(a), and postprandial triglycerides. Observational data indicate that a large majority of patients with overt hypothyroidism have some form of dyslipidemia.
The HDL picture is subtler and, by now, familiar. HDL concentration changes are inconsistent in hypothyroidism, but HDL function is reportedly impaired. Once again, the number can look fine while the particle is not doing its job.
Subclinical hypothyroidism, where TSH is elevated but free T4 remains in range, is less consistent in the research. Some patients show clear lipid elevations and some do not, and the benefit of treating mild cases specifically to improve lipids has not been established. TSH above 10 mU/L appears to be the level at which cardiovascular risk associations become most convincing. This is a place for clinical judgment rather than reflexive treatment.
Hypothyroidism is formally listed among the secondary causes of dyslipidemia that should be excluded before starting lipid-lowering therapy. There are two good reasons for that.
First, treating the thyroid often corrects the lipids. In overt hypothyroidism, thyroid hormone replacement restores LDL receptor-mediated clearance and reverses the lipid abnormalities. Treating the actual cause resolves the downstream problem, which is the entire premise of root-cause medicine.
Second, starting a statin in someone with undiagnosed hypothyroidism meaningfully increases the risk of statin-associated muscle symptoms. A patient can end up on a medication they may not need, experiencing side effects that could have been avoided, while the underlying condition goes untreated.
This is where conventional screening frequently falls short. A single TSH value can look acceptable while meaningful thyroid dysfunction is present underneath it.
A complete thyroid evaluation includes:
Conversion matters here as much as production. You can manufacture adequate T4 and still convert it poorly to T3, and T3 is the form that drives receptor expression in the liver. Nutrient status affects that conversion directly, particularly selenium, zinc, iron, and iodine. So does chronic stress, gut dysfunction, and inflammation.
This is why we evaluate thyroid function as a system rather than as a single screening value, and why we consider it early in any workup for unexplained cholesterol elevation.
If your LDL rose and nothing about your life changed, thyroid is one of the first places we look.
This question comes up frequently, and it deserves a straight answer rather than a reassuring one.
The concern is biologically reasonable on its face. The brain is the most cholesterol-rich organ in the body. Cholesterol builds myelin and supports synapse formation. ApoE, the brain’s primary lipid transporter, carries the single largest genetic risk factor for late-onset Alzheimer’s disease in its E4 form.
Some observational data appear to support the worry. In a Korean national cohort of nearly 6.9 million adults, dementia risk followed an inverted J-shaped curve, with the highest risk in the lowest LDL group among people not taking statins.
There is one legitimate open question, and the AHA raised it themselves. The randomized evidence extends roughly six years. Dementia develops over decades. No one has maintained a middle-aged population at very low LDL for thirty years and then counted diagnoses.
Acknowledging that gap is important.
We want to be straightforward with you: this is an area of active disagreement among serious researchers.
The mainstream position, supported by genetics, Mendelian randomization, and decades of trial data, holds that apoB-containing lipoproteins are causal in atherosclerosis, and that U-shaped mortality curves reflect confounding and reverse causation that statistical adjustment cannot fully eliminate.
The alternative position holds that LDL-C alone is a poor predictor for any individual, that absolute risk reduction from lowering it in primary prevention is smaller than commonly presented, and that risk assessment should rely on particle count, Lp(a), inflammation, metabolic markers, and imaging.
Here is what we find encouraging. Both camps arrive at nearly the same practical recommendation: measure more than LDL-C.
At The Fork Functional Medicine, advanced cardiovascular assessment is built into our treatment experience.
When patients begin their journey with us, cardiovascular risk is evaluated as part of a comprehensive picture rather than in isolation. That includes:
This is what allows us to distinguish between a patient who needs aggressive lipid management, a patient whose thyroid is driving the entire picture, and a patient whose numbers shifted because she is moving through menopause. Those three people have the same lab abnormality and three completely different root causes.
Treating them identically is exactly the problem with one-size-fits-all medicine.
A single cholesterol number was always a stand-in for something we could not easily measure. That is no longer the case.
We can count your particles. We can look at your genetic risk. We can assess the inflammation actively damaging your artery walls. We can identify the hormonal and thyroid drivers behind a panel that suddenly changed. And we can look directly at your arteries with calcium scoring rather than estimating your odds from a population average.
If you have been told your cholesterol is fine, you deserve to know whether that is actually true. If you have been told it is high, you deserve to know why before you jump to a statin.
That is not skepticism. That is precision.
Read more to learn more about how advanced cardiovascular testing is integrated into The Fork Functional Medicine.
References
The Fork Functional Medicine
200 9th Ave S.
Franklin, TN 37064
Phone: (615) 721-8008
Fax: (615) 237-8331
Monday: 9am - 5pm
Tuesday: 9am - 5pm
Wednesday: 9am - 5pm
Thursday: 9am - 5pm
Friday: CLOSED
Saturday-Sunday: CLOSED
By appointment only
Telemedicine visits are available to patients in the State of Tennessee. See further information under patient info.
Copyright 2025 The Fork Functional Medicine. All rights reserved. Website by Wink Digital.